SMC approves bimekizumab for hidradenitis suppurativa treatment - PharmaTimes The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not

#dermatology #immunology #UCB #SMC #SMCapprovel #bimekizumab #hidradenitissuppurativa #HS #hidradenitissuppurativatreatment #ScottishMedicinesConsortium #NHSScotland #HSpatients #phase3clinicaltrial #BEHEARDI #BEHEARDII #clincialstudies #patientoutcomes
pharmatimes.com/news/smc-app...